Prävention der Reokklusion

• LITERATUR

• 1 Gruppo italiano per lo studio della strepto-chinasi nell’infarto miocardico (GISSI).. Long-term effects of intravenous thrombolysis in acute myocardial infarction. Final report of the GISSI Study. Lancet 1987; II: 871-4.
• 2 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; II: 349-60.
• 3 Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477-82.
• 4 The GUSTO Investigators.. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
• 5 The GUSTO Angiographic Investigators.. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
• 6 Stouffer GA, Smedtje JF, Gulba D. et al. Restenosis following percutaneous revascularization – the potential role of thrombin and the thrombin receptor. Ann Hematol 1996; 73 suppl. I: S39-S41.
• 7 Smalling RW, Bode C, Kalbfleisch J. et al. and the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-32.
• 8 Grines CL, Browne KF, Rothbaum D. et al. for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-9.
• 9 Zijlstra F, de Boer MJ, Hoorntje JCA. et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-4.
• 10 Gibbons RJ, Holmes DR, Reeder GS. et al. for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685-91.
• 11 Ribeiro EE, Silva LA, Carneiro R. et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993; 22: 376-80.
• 12 Gulba DC, Bode C, Topp J. et al. Die Häufigkeit von Residualthromben nach erfolgreicher Thrombolysetherapie bei akutem Herzinfarkt und ihre Bedeutung für die Rate früher Reokklusionen. Ein Bericht der multizentrischen Dosisfindungsstudie zur Thrombolysetherapie mit Urokinase-präaktivierter natürlicher Prourokinase (TCL 598). Z Kardiol 1990; 79: 279-85.
• 13 Gulba DC, Bartheis M, Westhoff-Bleck M. et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 1991; 83: 937-44.
• 14 Chesebro JH, Knatterud G, Rogerts R. et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-54.
• 15 Gash AK, Spann JF, Sherry S. et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986; 57: 157-77.
• 16 Gulba DC, Bode C, Sen S. et al. and the German Preactivated Pro-Urokinase Study Group. Multicenter close-finding trial for thrombolysis with urokinase preactivated Pro-urokinase (TCL 598) in acute myocardial infarction. Cath Cardiovasc Diagn 1992; 26: 177-84.
• 17 Gulba D, Bartheis M, Reil GH, Lichtlen P. Thrombin-antithrombin-III-complex level as early predictor of reocclusion after successful thrombolysis. Lancet 1988; 2: 97.
• 18 DeBono DP, Simoons ML, Tijsen J. et al. for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-8.
• 19 Hsia J, Hamilton WP, Kleiman N. et al. for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-7.
• 20 Bleich SD, Nichols TC, Schumacher RR. et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-7.
• 21 Gold HK, Leinbach RC, Garabedian HD. et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347-52.
• 22 Harrison DG, Ferguson DW, Collins SM. et al. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation 1984; 69: 991-9.
• 23 Gulba DC, Daniel WG, Simon R. et al. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. JACC 1990; 80: 1-5.
• 24 Rapold HJ, Kuemmerli H, Weiss M. et al. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 980-9.
• 25 Eisenberg PR, Sherman L, Rich M. et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. JACC 1986; 7: 1255-62.
• 26 Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intensive fibrinolysis. JACC 1987; 10: 527-9.
• 27 Seitz R, Blanke H, Prätorius G. et al. Increased thrombin activity during thrombolysis. Thromb Haemost 1988; 59: 541-2.
• 28 Marder VJ, Shulmann NR. High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanisms of their anticoagulant activity. J Biol Chem 1969; 244: 2120-4.
• 29 Bartheis M, Gulba D, Engel MJ. Systemic fibrinolysis as an effect of intracoronary thrombolysis. In: Davidson JF, Donati MB, Cocchieri S. (eds) Progress in Fibrinolysis VII. Edinburgh: Churchill Livingstone; 1985: 49-51.
• 30 Briigemann J, van der Meer J, Takens BH. et al. A systemic non-lytic state and local thrombolytic failure of antistreplase (anisoy-lated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction. Br Heart J 1990; 64: 355-8.
• 31 Staniforth DH, Smith RAG, Hibbs M. Streptokinase and anisoylated streptokinase plasminogen complex: their action on he-mostasis in human volunteers. Eur J Clin Pharmacol 1983; 24: 751-6.
• 32 Neuhaus KL, von Essen R, Vogt A. et al. für die TAPS-Studiengruppe. Frühe Patency von Infarktgefäßen nach beschleunigter Infusion von 100 mg rt-PA vs. 30 mg APSAC: Ergebnisse der TABS-Studie. Z Kardiol 1991; 80(Suppl. 3): 93 (Abstract)
• 33 Neuhaus KL, Tebbe U, Gottwik M. et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German activator urokinase study (GAUS). JACC 1988; 12: 581-7.
• 34 Bartheis M, Gulba D, Bohn U. et al. Effects of plasminogen activators on the coagulation system. Blut 1990; 60: 154 (Abstract)
• 35 Hoffmeister HM, Jur M, Ruf M. et al. Strep-tokinasetherapie bei akutem Myocardin-farkt führt zur polongierten Aktivierung des Kallikrein-Kininsystems. Z Kardiol 1994; 83, (Suppl 1): A356.
• 36 Ewald GA, Eisenberg PR. Increased procoagulant activity in response to fibrinolytic agents due to plasmin-mediated activation of the contact system. Thromb Haemost 1993; 69: 823 (Abstract)
• 37 Seitz R, Pelzer H, Egbring R. Activation of prothrombin in patients with acute myocardial infarction (AMI) and in vitro by thrombolytic agents. Ann Hematol 1991; 1 suppl A A76 (Abstract).
• 38 Simoons ML, Arnold AER, Betriu A. et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. The Lancet 1988; 1: 197-203.
• 39 The TIMI Study Group.. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-27.
• 40 Topol EJ, Califf RM, George BS. et al. and the Thrombolysis and Angioplasty in Myocardial Infarction Study Group : A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581-8.
• 41 Verheught FWA, Meijer A, Werter CJ. Antithrombotics in the prevention of reocclu-sion in coronary thrombolysis: the APRICOT study. Vorträge gehalten anläßlich der 13. Jahrestagung der European Society of Cardiology, Amsterdam 18.-22. August 1991. (unveröffentlicht).
• 42 Gersh BJ, Opie LH. Antithrombotic agents: platelet inhibitors, anticoagulants and fibrinolytics. In: Opie LH. (ed) Drugs for the Heart. Philadelphia: Saunders; 1995
• 43 Pietrolungo JF, Topol EJ. Thrombolytic and new antiplatelet agents. In: Ellis SG, Holmes DR. (eds) Strategic Approaches in Coronary Intervention. Baltimore: Williams & Wilkins; 1996
• 44 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occuring thrombin inhibitors. Thromb Res 1986; 47: 613-20.
• 45 Walsmann P, Kaiser B. Biochemical and pharmacological properties of recombinant hirudin. Drugs of Today 1989; 25: 473-85.
• 46 Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992; 10, No 2: 211-32.
• 47 Lee LV. for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial Infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995; 75: 7-13.
• 48 Molhoek GP, Laarman GJ, Lok DJA. et al. Effects of recombinant hirudin (HBW 023) on early and late coronary patency in myocardial infarction patients treated with streptokinase (the HIT-SK Study). Eur Heart J 1995; 16: 177 (Abstract).
• 49 Cannon CP, McCabe CH, Henry TD. et al. A pilot trial of recombinant desulfato-hiru-din compared with heparin in conjunction with tissue-type plasminogen activator and aspirin in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
• 50 Antman EM. for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
• 51 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ha Investigators.. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
• 52 Neuhaus K-L, v. Essen R, Tebbe U. et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994; 90: 1638-42.
• 53 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lib investigators.. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
• 54 Tripoldi A, Chantarangkul V, Arbini AA. et al. Effects of hirudin on activated partial thromboplastin time determined with ten different agents. Thromb Haemost 1993; 70: 286-8.
• 55 Esslinger HU, Greger G, Labmann A, Maurer R. General tolerability and effects on clotting parameters after single i.v. and s.c. bolus administratiion of recombinant hirudin (LU 52369) in man. Thromb Haemost 1991; 65(Suppl): 1291 (Abstract).
• 56 Haas S, Esslinger HU, Stemberger A. et al. Placebo-controlled trial on the anticoagulant effects of PRG-Hirudin (LU 57291) as intravenous infusion in healthy volunteers. Ann Haematol 1995; 70 suppl. I A45 (Abstract).
• 57 Born GVR. Platelets in atherogenesis and thrombogenesis. In: Kakkar VV. (ed) Atheroma and Thrombosis. London: Pitman Publishing Ltd.; 1985: 143-52.
• 58 Firkin BG. The Platelet and Its Disorders. Lancaster: MTP Press; 1984
• 59 Benett JS. The molecular biology of the platelet membrane proteins. Semin Haematol 1990; 27: 186-204.
• 60 Nurden AT, George JN, Phillips DR. Platelet membrane glycoproteins: their structure, function and modification in disease. In: Phillips DR, Shuma MA. (eds) Biochemistry of Platelets. New York: Academic Press; 1986: 159-224.
• 61 Peerschke EI. The platelet fibrinogen receptor. Semin Haematol 1985; 22: 241-59.
• 62 Niewiarowski S, Holt JC. Platelet alpha granule proteins. Biochemical and physiological aspects. In: Langenecker GL. (ed) Biochemistry of Platelets. New York: Academic Press; 1985: 49-83.
• 63 Coller B. Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med 1992; 43: 171-80.
• 64 Coller BS, Scudder LE. Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glykoprotein Ilb/IIIa receptor. Blood 1985; 66: 1456-9.
• 65 Ellis SG, Tscheng JE, Navetta FI. et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein Ilb/IIIa in patients undergoing elective coronary angioplasty. Cor Art Dis 1993; 4: 167-75.
• 66 Tcheng JE, Ellis SG, George BS. et al. Pharmacodynamics of chimeric glycoprotein Ilb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-64.
• 67 The EPIC Investigators.. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
• 68 Topol EJ, Califf RM, Weisman HF. et al. on behalf of the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet GP Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
• 69 Yasada T, Gold HK, Leinbach RC. Lysis of plasminogen activator resistant platelet rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GP Ilb/IIIa antibody. J Am Coll Cardiol 1990; 16: 1728-35.
• 70 Ohman M, Kleiman N, Talley D. et al. for the IMPACT-AMI study group. Simultaneous platelet glycoprotein Ilb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation 1994; 90 suppl 1-564 (Abstract).
• 71 Kleiman NS, Ohman EM, Califf RM. et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab after thrombolytic therapy. JACC 1993; 22: 381-9.
• 72 Schömig A, Neumann FJ, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
• 73 Colombo A, Nakamura S, Almagor Y. et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-88.
• 74 Serruys PW, de Jaegere P, Kiemeneij F. et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-5.
• 75 Fischman DL, Leon MB, Bairn DS. et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl JMed 1994; 331: 496-501.
• 76 Ahmad T, Webb JG, Garere RR, Dodek A. Coronary stenting for acute myocardial infarction. Am J Cardiol 1995; 76: 77-80.